Opportunity Information: Apply for PAR 25 116
This NIH grant opportunity (PAR-25-116) uses the R01 mechanism to support research that clarifies how infections can lead to lasting neurological and mental health-related problems. The main focus is on infection-associated chronic illnesses where symptoms persist well beyond the initial infection, including post-acute sequelae of COVID-19 with neurological involvement (often referred to as Neuro-PASC or neurological long COVID). It also explicitly includes other conditions believed to have an infectious trigger or post-infectious course, such as post-treatment Lyme disease, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), postural orthostatic tachycardia syndrome (POTS), and other post-viral fatigue syndromes. The overall aim is to move beyond description of symptoms and toward a better, mechanism-level understanding of what is happening in the nervous system and related biological systems that influence brain and behavior.
A central theme of the NOFO is the encouragement of studies that dig into biologically plausible, scientifically compelling pathways that could explain why some people develop persistent neurological or neuropsychiatric symptoms after an infection. The opportunity is broad in the sense that applications can focus on one condition, but it places particular value on projects that look for shared mechanisms across multiple post-infectious illnesses. In practice, that means NIH is signaling strong interest in research that can identify converging biology (for example, overlapping immune, vascular, autonomic, metabolic, or neuroinflammatory signatures) that might explain common symptom clusters such as cognitive dysfunction, fatigue, dysautonomia, headache, sleep disruption, mood changes, or other mental health-related manifestations. Even when a project is centered on a single diagnosis, it should be framed in a way that clearly ties the proposed biology to a post-infectious etiology rather than unrelated causes of similar symptoms.
The NOFO makes clear that several types of research designs are considered in-scope. Neurologically oriented clinical research is strongly emphasized, including basic experimental studies in humans (BESH), which typically involve intensive human phenotyping or experimental approaches aimed at understanding mechanisms rather than testing a large-scale clinical efficacy endpoint. Mechanistic clinical trials are also allowable (the announcement is labeled "Clinical Trial Optional"), particularly when they are designed to test a mechanistic hypothesis and accelerate progress toward effective treatments. The key is that the trial component should illuminate biological pathways that contribute to the development or persistence of illness, rather than functioning purely as a pragmatic effectiveness trial with minimal mechanistic measurement.
In addition to human studies, the opportunity explicitly welcomes preclinical work. That includes studies using animal models, cell culture systems, or human tissue-based models, as long as the scientific question remains anchored to post-infectious disease mechanisms relevant to these chronic conditions. This allows applicants to use controlled systems to probe causality, identify candidate pathways, test how infection or infection-triggered immune responses affect neural function, or evaluate interventions at a mechanistic level before or alongside human studies. Across all approaches, the common requirement is that the proposed work must be situated in the context of a post-infectious trigger or etiology.
From an applicant and eligibility standpoint, this is a discretionary NIH grant in the health category (CFDA 93.242 and 93.853), and it is open to a wide range of organizations. Eligible applicants include many levels of government (state, county, city/township, special districts), public and private institutions of higher education, independent school districts, tribal governments and tribal organizations, public housing authorities/Indian housing authorities, and both nonprofit and for-profit entities (including small businesses, though the mechanism is R01 rather than an SBIR/STTR). The NOFO also highlights inclusion of institutions and organizations that often participate in federal research funding programs, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs). Faith-based and community-based organizations, regional organizations, U.S. territories or possessions, and non-U.S. (foreign) entities are also listed as eligible, signaling NIH interest in broad participation and potentially diverse study populations or international collaborations where scientifically justified.
Key administrative details included in the listing are the opportunity title "Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)," the funding opportunity number PAR-25-116, and the original closing date of 2025-11-05. The award ceiling and expected number of awards are not specified in the provided source data, which often means applicants should rely on standard NIH R01 budgeting norms and ensure their scope and budget are well-justified and aligned with the complexity of the proposed work. Overall, the opportunity is positioned to fund rigorous, mechanism-driven research that can explain persistent neurological and mental health-related symptoms after infection and, importantly, generate insights that speed the path toward targeted, effective interventions.Apply for PAR 25 116
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242, 93.853.
- This funding opportunity was created on 2024-10-17.
- Applicants must submit their applications by 2025-11-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the NIH funding opportunity and what does it support?
This NIH opportunity, PAR-25-116, uses the R01 mechanism to support research aimed at explaining how infections can lead to long-lasting neurological and mental health-related problems. The emphasis is on moving beyond describing symptoms and toward mechanism-level understanding of what is happening in the nervous system and related biological systems that influence brain and behavior.
What is the official title of this opportunity?
The opportunity title is "Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)."
What is the funding opportunity number?
The funding opportunity number is PAR-25-116.
What types of conditions are included within the scope of this NOFO?
The NOFO focuses on infection-associated chronic illnesses where symptoms persist well beyond the initial infection. It explicitly includes post-acute sequelae of COVID-19 with neurological involvement (Neuro-PASC or neurological long COVID). It also includes other conditions believed to have an infectious trigger or post-infectious course, such as post-treatment Lyme disease, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), postural orthostatic tachycardia syndrome (POTS), and other post-viral fatigue syndromes.
Is neurological long COVID (Neuro-PASC) specifically included?
Yes. The NOFO explicitly includes post-acute sequelae of COVID-19 with neurological involvement, often referred to as Neuro-PASC or neurological long COVID.
Does the opportunity allow research focused on conditions besides COVID-19?
Yes. In addition to Neuro-PASC, the NOFO explicitly includes other post-infectious or infection-triggered conditions (for example, post-treatment Lyme disease, ME/CFS, POTS, and other post-viral fatigue syndromes).
What is the main scientific emphasis: symptom description or biological mechanisms?
The main emphasis is on biological mechanisms. The NOFO is positioned to move beyond describing symptoms and toward understanding the pathways and system-level biology that could explain persistent neurological or neuropsychiatric symptoms after infection.
What kinds of symptoms or manifestations are highlighted as relevant?
The NOFO highlights interest in research that could explain common symptom clusters such as cognitive dysfunction, fatigue, dysautonomia, headache, sleep disruption, mood changes, and other mental health-related manifestations.
Does NIH encourage studying shared mechanisms across multiple post-infectious illnesses?
Yes. While applications can focus on one condition, the NOFO places particular value on projects that look for shared mechanisms across multiple post-infectious illnesses and identify converging biology that could explain common symptom clusters.
Can an application focus on a single diagnosis?
Yes. The opportunity is broad and allows applications centered on one condition. However, even single-condition projects should clearly connect the proposed biology to a post-infectious etiology rather than unrelated causes of similar symptoms.
What types of biological pathways does the NOFO consider relevant?
The NOFO encourages studies that investigate biologically plausible and scientifically compelling pathways. Examples of pathway areas mentioned include immune, vascular, autonomic, metabolic, or neuroinflammatory signatures that may overlap across conditions.
What study designs are considered in-scope on the clinical research side?
Neurologically oriented clinical research is strongly emphasized, including basic experimental studies in humans (BESH), which often involve intensive human phenotyping or experimental approaches designed to understand mechanisms.
What are basic experimental studies in humans (BESH) in the context of this NOFO?
In this NOFO, BESH refers to human studies that tend to involve intensive phenotyping or experimental approaches intended to uncover mechanisms, rather than large pragmatic studies aimed primarily at testing clinical efficacy endpoints.
Are clinical trials allowed under this opportunity?
Yes. The NOFO is labeled "Clinical Trial Optional," and mechanistic clinical trials are allowable when they test a mechanistic hypothesis and help clarify biological pathways contributing to the development or persistence of illness.
What kind of clinical trial fits best with the NOFO’s intent?
Trials that are designed to illuminate mechanisms (for example, trials that include mechanistic measurements to test a biological hypothesis about persistence or progression) fit the NOFO’s intent. The focus should not be a purely pragmatic effectiveness trial with minimal mechanistic measurement.
Is preclinical research allowed (animal models, cell culture, tissue-based models)?
Yes. The opportunity explicitly welcomes preclinical work, including animal models, cell culture systems, and human tissue-based models, as long as the questions remain anchored to post-infectious disease mechanisms relevant to these chronic conditions.
What is the unifying requirement across human and preclinical approaches?
Across all approaches, the proposed work must be situated in the context of a post-infectious trigger or etiology and remain focused on mechanisms relevant to infection-associated chronic illnesses with neurological and/or mental health-related outcomes.
Is this considered a discretionary NIH grant and what category is it listed under?
Yes. The listing describes it as a discretionary NIH grant in the health category, associated with CFDA 93.242 and 93.853.
Who is eligible to apply?
The NOFO is open to a wide range of organizations, including many levels of government (state, county, city/township, special districts), public and private institutions of higher education, independent school districts, tribal governments and tribal organizations, public housing authorities/Indian housing authorities, and nonprofit and for-profit entities (including small businesses).
Are small businesses eligible even though this is not an SBIR/STTR?
Yes. The eligibility list includes for-profit entities (including small businesses), although the mechanism is R01 rather than SBIR/STTR.
Are specific institution types (like HBCUs or HSIs) called out as eligible?
Yes. The NOFO highlights participation by institutions and organizations that often participate in federal research funding programs, including HBCUs, Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and AANAPISIs.
Are faith-based and community-based organizations eligible?
Yes. Faith-based and community-based organizations are listed as eligible.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are listed as eligible.
Are non-U.S. (foreign) entities eligible?
Yes. Non-U.S. (foreign) entities are listed as eligible, supporting the possibility of international participation or collaborations where scientifically justified.
What is the application due date provided in the listing?
The original closing date listed is 2025-11-05.
Is there an award ceiling listed or a specified expected number of awards?
No. The provided source data does not specify an award ceiling or the expected number of awards.
How should applicants think about budget given the lack of an award ceiling in the listing?
Because the award ceiling is not specified in the provided information, applicants are expected to rely on standard NIH R01 budgeting norms and ensure the requested budget is well-justified and aligned with the scope and complexity of the proposed work.
What is the overall goal or impact NIH is trying to achieve with this opportunity?
The overall goal is to fund rigorous, mechanism-driven research that can explain persistent neurological and mental health-related symptoms after infection, and generate insights that can speed progress toward targeted, effective interventions.
Browse more opportunities from the same category: Health
Next opportunity: National Animal Disease Preparedness and Response Program Fiscal Year 2025 Tribal Funding Opportunity Announcement
Previous opportunity: Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 25 116
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 25 116) also looked into and applied for these:
| Funding Opportunity |
|---|
| BURMA: Resilient Tuberculosis Response in Myanmar (RTBR) Activity Apply for 72048225RFA00001 Funding Number: 72048225RFA00001 Agency: Burma USAID - Rangoon Category: Health Funding Amount: $13,500,000 |
| USAID Maisha Bora Activity Apply for 72066024RFA00007 Funding Number: 72066024RFA00007 Agency: Democratic Republic of the Congo USAID-Kinshasa Category: Health Funding Amount: $15,000,000 |
| Strengthening Systems for Health Security Activity (SSHS) Apply for 72052725RFA00001 Funding Number: 72052725RFA00001 Agency: Peru USAID-Lima Category: Health Funding Amount: $19,000,000 |
| TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) (U54 Clinical Trial Optional) Apply for RFA DE 25 003 Funding Number: RFA DE 25 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional) Apply for PAR 25 120 Funding Number: PAR 25 120 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Comprehensive Analysis, Surveillance, and Statistics Initiative for Diabetes in the Young (CASSIDY) Apply for RFA DP 25 043 Funding Number: RFA DP 25 043 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $700,000 |
| Connecting Organizations and People to Empower Diabetes Prevention and Treatment (Connections) Apply for RFA DP 25 041 Funding Number: RFA DP 25 041 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $350,000 |
| Epilepsy Incidence Among Children in the United States Apply for RFA DP 25 038 Funding Number: RFA DP 25 038 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $500,000 |
| Advancing Public Health Actions to Prevent and Control Chronic Disease in the U.S. Territories and Freely Associated States Apply for CDC RFA DP 25 0024 Funding Number: CDC RFA DP 25 0024 Agency: Centers for Disease Control - NCCDPHP Category: Health Funding Amount: $1,400,000 |
| Centers of Excellence in Maternal and Child Health Education, Science, and Practice Apply for HRSA 25 027 Funding Number: HRSA 25 027 Agency: Health Resources and Services Administration Category: Health Funding Amount: $366,769 |
| Maternal and Child Health Public Health Catalyst Program Apply for HRSA 25 025 Funding Number: HRSA 25 025 Agency: Health Resources and Services Administration Category: Health Funding Amount: $135,000 |
| Behavioral Health Workforce Education and Training Program for Professionals Apply for HRSA 25 068 Funding Number: HRSA 25 068 Agency: Health Resources and Services Administration Category: Health Funding Amount: $600,000 |
| Graduate Psychology Education Program (GPE) Apply for HRSA 25 067 Funding Number: HRSA 25 067 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) Apply for PAR 25 058 Funding Number: PAR 25 058 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed) Apply for PAR 25 059 Funding Number: PAR 25 059 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed) Apply for PAR 25 060 Funding Number: PAR 25 060 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Centers for Accelerating Phage (Bacteriophage) Therapy to Combat ESKAPE Pathogens (CAPT-CEP) (P01 Clinical Trial Not Allowed) Apply for RFA AI 24 069 Funding Number: RFA AI 24 069 Agency: National Institutes of Health Category: Health Funding Amount: $1,200,000 |
| Pilot projects to enhance utility and usage of data sets from the Molecular Transducers of Physical Activity Consortium (MoTrPAC) (R03 Clinical Trials Not allowed) Apply for RFA RM 24 011 Funding Number: RFA RM 24 011 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) Apply for PAR 25 057 Funding Number: PAR 25 057 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Human Virome Program: Developing novel and innovative tools to interrogate and annotate the human virome (U01 Clinical Trial Not Allowed) Apply for RFA RM 24 009 Funding Number: RFA RM 24 009 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 25 116", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.